Alcidion Group Limited advised that Alcidion co-founder Dr. Malcolm Pradhan is stepping down as Executive Director and Chief Medical Officer as part of a natural evolution and a well-established succession plan adopted by the board several years ago. Dr. Pradhan has been an architect of the Alcidion business for more than 22 years and has been a visionary, and important contributor, to building the Miya platform that is now well established in hospitals across Australia, New Zealand, and the United Kingdom With the Alcidion business now firmly in an execution stage and following the acquisition of ExtraMed and SilverLink last year, Dr. Pradhan has decided that the timing was now right for him to step away. Over that last 2-3 years Alcidion has invested in building its capabilities across leadership and the company and is well placed to continue to execute on the product vision laid out by Dr. Pradhan.

This next phase requires a greater focus on roles directed towards product delivery and execution. Under the ASX Listing Rules, Dr. Pradhan was listed for re-election to the Board at the Annual General Meeting (AGM) for 30th November 2022. Dr. Pradhan will not be seeking re-election and will now retire as a director (and executive) immediately following the AGM.

There will be an announcement from the Company withdrawing the resolution for Dr. Pradhan's nomination as a director to follow.